Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
87 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ordensklinikum Linz Gmbh
Linz, Austria
- Landesklinikum Wiener Neustadt
Wiener Neustadt, Austria
- Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
- Universitair Ziekenhuis Gent
Ghent, Belgium
- Universitair Ziekenhuis Leuven
Leuven, Belgium
- Institut Sainte Catherine - Institut Du Cancer Avignon Provence
Avignon, France
- Centre Hospitalier Régional Universitaire de Besançon
Besançon, France
- Hopital Beaujon
Clichy, France
- Hopital Franco-Britannique - Fondation Cognacq-Jay
Levallois-Perret, France
- Clinique de la Sauvegarde
Lyon, France
- Centre Hospitalier Universitaire de Montpellier
Montpellier, France
- Hopital Saint Antoine
Paris, France
- Institut de Cancerologie Gustave Roussy
Villejuif, France
- Krebszentrum Reutlingen
Baden, Germany
- Krankenhaus Nordwest Ggmbh
Frankfurt, Germany
- Asklepios Klinik Altona
Hamburg, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitaetsklinikum Heidelberg (ukhd) - Nationales Centrum Fuer Tumorerkrankungen Heidelberg (nct)
Heidelberg, Germany
- Ludwig-Maximilians-Universität München Kum
München, Germany
- Clinica Oncologica, Ospedali Riuniti Umberto 1
Ancona, Italy
- Candiolo Cancer Institute - Fpo Irccs
Candiolo, Italy
- Istituto Scientifico Romagnolo Per Lo Studio E la Cura Dei Tumori
Meldola, Italy
- Asst Grande Ospedale Metropolitano Niguard
Milan, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
- Istituto Europeo Di Oncologia Irccs
Milan, Italy
- Azienda Ospedaliera Universitaria Luigi Vanvitelli
Naples, Italy
- Istituto Nazionale Tumori Irccs Fondazione G. Pascale
Naples, Italy
- Azienda Ospedaliera Universitaria Di Parma
Parma, Italy
- Azienda Ospedaliero-Universitaria Pisana
Pisa, Italy
- Humanitas Research Hospital
Rozzano, Italy
- Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte
Siena, Italy
- Aoui Verona - Ospedale Borgo Roma
Verona, Italy
- Amsterdam Umc, Location Amc
Amsterdam, Netherlands
- Centrum Onkologii-Instytut Im. Marii Skłodowskiej-Curie
Warsaw, Poland
- Centro Hospitalar Lisboa Norte Chln Epe - Hospital de Santa Maria
Lisbon, Portugal
- Fundação Champalimaud
Lisbon, Portugal
- Cha Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
- Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea
- Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
- Dong-A University Hospital
Busan, South Korea
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Dec 2023
- Primary completion
- 31 Dec 2026
- Completion
- 31 Dec 2026
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 200
- Registry id
- NCT05948475
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.